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Abstract The pokeweed antiviral protein (PAP) has already 
been used to chemically construct immunotoxins. Here we tested 
the recombinant approach for the production of PAP-containing 
cytotoxic fusion-proteins. A cDNA encoding a mutated PAP 
(PAP9), which is expressed at high levels in bacteria, was fused 
to human interleukin-2 (IL-2) cDNA. The resulting PAP9-IL-2 
protein was as active as the free PAP9 in inhibiting an eukaryotic 
cell-free translation system. Only the chimeric protein desami-
nated the 28S rRNA and inhibited translation of the CTLL-2 cell 
line which expresses the IL-2 receptor. These results show that 
PAP is a suitable toxin for the production of recombinant 
immunotoxins. 
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1. Introduction 
The pokeweed antiviral protein (PAP), like other iV-glyco-
sidases, inactivates eukaryotic ribosomes and therefore inhib-
its the protein-synthesis process. Ribosome inactivation has 
been correlated with removal of one adenine residue of the 
large ribosomal R N A (rRNA). This adenine is located in an 
evolutionary conserved region and corresponds to position 
4324 for rat liver 28S r R N A [1]. The ribosomes of Phytolacca 
americana, the PAP-producing plant, are also susceptible to 
PAP depurination [2]. 
The sequences of different forms of PAP produced by P. 
americana have been determined at the c D N A or protein lev-
els [3-6]. The 3-dimensional structure has been established for 
PAP by X-ray crystallography to 2.5 A resolution [7] and 
compared to that of the A-chain of ricin [8] for which key 
amino acids have been identified [9]. 
P A P has been chemically linked to antibodies in order to 
specifically kill cells expressing the epitope recognized by the 
antibody part of the resulting immunotoxins, and clinical tri-
als have been performed with a potent immunotoxin (B43-
PAP) against B-lineage leukemia/lymphoma cells [10-13]. In 
addition, PAP appeared to be a suitable ribosome-inactivating 
protein for the production of recombinant cytotoxic fusion 
proteins [14]. Here we produced and tested the cytotoxic ac-
tivity of a recombinant hybrid protein composed of human 
interleukin-2 (IL-2) and a mutated form of PAP (PAP9) 
which allows Escherichia coli growth and is expressed at 
high levels in bacteria [15]. 
*Corresponding author. Fax: (0381) 41-36-36. 
2. Materials and methods 
2.1. Construction and expression 
The pBluescript KS vector digested with Kpnl and Hindlll was 
ligated with both (i) the IL-2 insert of BBG3 (R and D Systems, 
Europe) digested with Xho\, treated with the Klenow DNA polymer-
ase and digested with HinálW and (ii) the insert of the pBluescript KS 
clone of PAP9 digested with AccI, treated with the Klenow DNA 
polymerase and digested with Knpl. The insert of a positive clone 
was then transfered into the pKK233.2 expression vector by using 
Nco\ and Hiná\\\ enzymes. The first three N-terminal amino acids 
of IL-2 have been deleted during the construction. 
The proteins were expressed in E. coli and the inclusion body frac-
tion isolated, solubilized and renatured by dialysis as previously de-
scribed for PAP [15]. The preparations were analyzed on SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE) and stained with 
Coomassie brilliant blue to estimate the relative amounts of recovered 
recombinant proteins. 
2.2. In vitro activity 
The activity of the recombinant proteins was tested in vitro using 
the reticulocyte protein synthesizing kit type II (Boehringer) as pre-
viously described [15]. 
2.3. Cytotoxicity 
The CTLL-2 cell line was maintained in RPMI-8866 medium com-
plemented with 20% inactivated fetal calf serum, 4 mM L-glutamine, 
100 IU/ml penicillin, 100 Jig/ml streptomycin, 5X10~5 M ß-mercap-
toethanol and 0.4 ng/ml IL-2 in humidified air at 37°C and 5% C0 2 . 
The cells were washed twice in the same medium but without IL-2 and 
seeded in a 96-well plate at 2X104 cells/ml, to which the protein 
preparations were added. The cells were incubated 1 h at 4°C, then 
washed and incubated 45 h at 37°C in a medium containing IL-2. The 
medium was then replaced by a methionine-free medium and 30 min 
later 10 uCi of [3aS]methionine (Amersham) was added. After 2 h at 
37°C, the cells were lyzed with 0.1 M NaOH, the cell proteins pre-
cipitated with trichloracetic acid on glass-fiber filters, and the incor-
poration measured by liquid scintillation counting (microbeta 1450 
Wallac). The experiments were carried out in triplicate. 
2.4. Analysis of 28S rRNA desamination 
Desamination of 28S rRNA was analyzed by primer extension. The 
reaction was performed as described by Dore et al. [16] with RNA 
extracted from CTLL-2 murine cells. The oligodeoxynucleotide used 
is complementary with 28S rRNA from T4334 to T4350, a region 3' 
to position 4256 corresponding to the PAP desamination site. Reverse 
transcriptase stops at this position yielding a 94-nucleotide-long 
cDNA if adenine is absent. 
3. Results and discussion 
3.1. Construction and expression 
P A P alone has a very low toxicity for eukaryotic cells, but 
conjugates made with P A P and a monoclonal antibody (mAb) 
are highly cytotoxic immunotoxins for cells bearing the mAb-
epitope [10-13]. In addition, PAP appeared to be a suitable 
ribosome-inactivating protein for the production of recombi-
nant immunotoxins since an immunotoxin made with PAP 
remains cytotoxic when the linker used to bind the two pro-
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Dilutions of the protein preparations 
Fig. 1. Inhibition of a cell-free reticulocyte protein synthesis system. 
The level of incorporation of [35S]methionine into TCA-precipitable 
products was determined as percentage of the incorporation ob-
tained with a buffer-treated cell-free system. Analysis was done with 
PAP9 (shaded boxes) and PAP-IL-2 (black boxes) protein prepara-
tions. 
teins together is a non-cleavable agent [14]. This property is 
not shared by all ribosome-inactivating proteins [14]. 
To study the feasibility of this approach, a construction was 
made by fusing PAP to human IL-2. A clone coding for a 
mutated form of PAP, PAP9, which permits E. coli growth 
and is expressed at high levels in bacteria was used for the 
construction [15]. Since fusions made to the N-terminus of 
other iV-glycosidases reduced their activity [17,18], we choose 
to introduce IL-2 at the C-terminus of PAP9. 
P. americana plants very likely produce a PAP precursor 
since the protein isolated from the leaves of the plant does not 
contain the N- and C-terminal regions encoded by the cDNA. 
Our PAP9 clone encodes a protein containing the C-terminal 
extension of the putative precursor. The C-terminal extension 
being dispensable for the iV-glycosidase activity, the unique 
Accl restriction site present in the middle of this region was 
used to make the PAP9-IL-2 construct. The deduced amino 
acid sequence present between PAP9 and IL-2 and which 
corresponds to the remaining part of the C-terminal extension 
of PAP9 is: Y, N, Q, N, A, M, F, P, Q, L, I, M. 
E. coli cells tranformed with the construct were induced for 
expression. The inclusion body fraction, mainly containing the 
recombinant protein, was isolated, and a denaturation/renatu-
ration process was used to prepare the soluble protein. 
3.2. In vitro PAP9 activity 
The PAP9 activity of the chimeric protein was tested in a 
cell-free protein-synthesizing system and compared to that of 
the non-fused PAP9 protein (Fig. 1). The results showed that 
PAP9-IL-2 was as active as the non-fused PAP9 protein in 
inhibiting eukaryotic translation. Therefore PAP9 activity was 
not affected by the presence of the ligand. 
3.3. Cytotoxicity of PAP9-IL-2 
The biological activity of PAP9-IL-2 was tested using the 
CTLL-2 cell line. This murine cell line requires IL-2 to pro-
liferate and therefore expresses the IL-2 receptor. Since PAP9 
interrupts translation, cytotoxicity was followed by measuring 
the level of protein synthesis in the cells. The cells were pre-
incubated with PAP9 or PAP9-IL-2 protein preparations in a 
IL-2-free medium and then incubated in the medium contain-
ing IL-2. The results showed that PAP9-IL-2 inhibited cellu-
lar translation and that free PAP9 had no effect (Fig. 2). The 
level of inhibition was dependent on the amount of PAP9-IL-
2 protein added to the cells (Fig. 2). 
PAP inactivates ribosomes and therefore inhibits transla-
tion, its vV-glycosidase activity removing one adenine residue 
of the 28S rRNA. This adenine, located in an evolutionary 
conserved sequence, corresponds to position 4256 for mouse 
28S rRNA. To confirm that PAP9 activity of the hybrid pro-
tein was responsible for the cytotoxicity, after treatment we 
analyzed the integrity of 28S rRNA by primer extension (Fig. 
3). An oligodeoxynucleotide hybridizing with a region 3' to 
the targeted adenine was used as primer. The reverse tran-
scription reaction stops if a base is missing on the matrix 
RNA yielding, in our case, a 94-nucleotide-long cDNA if 
A4256 is absent. The 28S rRNA extracted from cells treated 
with PAP9-IL-2 (lane 3) was indeed desaminated. Such desa-
mination was neither observed with mock-treated (lane 1) nor 
with cells treated with PAP9 (lane 2). Inhibition of the trans-
lation correlated with the appearance of desaminated 28S 
Fig. 2. Activity of recombinant proteins on the protein synthesis of 
CTLL-2 cell line. Incorporation of [35S]methionine into TCA-precip-
itable products was referred to a positive control corresponding to 
buffer-treated cells. The cells were incubated with PAP9 or PAP9-
IL-2 protein preparations. Different dilutions of PAP9-IL-2 protein 
preparation were also tested. 
Fig. 3. Desamination analysis. Primer extensions were performed 
with RNAs extracted from mock-treated cells (lane 1), cells treated 
with PAP9 (lane 2) or with PAP9-IL-2 (lane 3) protein prepara-
tions. The specific cDNA, appearing if 28S rRNA had been desami-
nated by PAP activity, is visible in the middle of the figure. 
52 
r R N A s shows that PAP9 activity has been transported to the 
cytoplasm. Therefore P A P appeared to be a suitable ribo-
some-inactivating protein for the production of recombinant 
cytotoxic hybrid proteins, which are well-defined products. 
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